Business Wire

FLEXTRADE-SYSTEMS

9.9.2021 09:02:03 CEST | Business Wire | Press release

Share
FlexTrade First EMS to Integrate with Appital’s Pioneering Bookbuilding Platform

Appital, the Equity Capital Marketplace, today announced that FlexTrade Systems (@FlexTrade ), a global leader in multi-asset execution and order management systems, is the first EMS provider to integrate with Appital’s bookbuilding platform.

By working with pioneering firms like FlexTrade, Appital is driving the technological infrastructure development necessary to integrate their platform into existing market structures and bring innovation and automation to equity capital markets.

Appital’s platform will be fully integrated with FlexTrade’s FlexTRADER EMS, bringing a historically manual order flow process to an automated platform. Through FlexTrade’s integration with Appital, buy-side firms will have access to the liquidity and efficiency of executing on Turquoise, LSEG’s (London Stock Exchange Group) pan-European MTF with seamless straight-through-processing (STP) to over 20 settlement venues. Sparked by demand from some of the largest asset management firms globally, the integration will offer the buy-side community a more efficient and transparent way to execute large orders with minimal market impact or risk of price erosion.

Andy Mahoney, Managing Director EMEA FlexTrade Systems, commented: “This integration with Appital brings transparency and automation to an area of the market traditionally plagued by opacity and outdated, phone based bookbuilding activity. We see significant demand for Appital’s offering from some of our largest asset management customers. As a result, we have been collaborating with Appital to develop standard integration procedures to ensure our clients have seamless access to Appital’s platform directly within the FlexTRADER EMS order blotter to actively participate in the liquidity discovery process in the market for size.”

The integration with FlexTrade has led to the establishment of a working group that includes some of the largest asset managers globally. The group helps mutual clients define how they want to interact with the hard-to-find liquidity in the market and proactively build books of demand, while ensuring that the integration to existing workflows remains seamless. Other EMS providers are now able to code to the established, FIX based protocols, to the benefit of the buy-side community overall.

Dr Robert Barnes, CEO, Turquoise Global Holdings & Group Head of Securities Trading at London Stock Exchange Group, said: “Turquoise is pleased to build on our innovation in partnership with Appital to unlock latent liquidity for the market. Through FlexTrade’s integration, buy-side participants can look forward to Appital’s novel bookbuilding and seamless execution to settlement of liquidity at the right price through Turquoise.”

Mark Badyra, CEO of Appital, said : “In our mission to put buy-side firms in control of their bookbuilding activity we are excited to work with innovative firms like FlexTrade to help us shape the technology infrastructure for EMS integrations. FlexTrade clients and the asset management community can now gain exposure to deal flow opportunities they have not been able to access before. This integration transforms a traditionally manual order flow process, that historically sits outside any EMS, into an automated, electronic platform.

Badyra added: “FlexTrade has been instrumental in developing the Appital workflow alongside ourselves and the team at Turquoise. This is a major step forward for not only our combined client base, but the market as a whole, and we look forward to scaling this integration market-wide in the coming months.”

Appital gives the buy-side community greater exposure to deal flow opportunities they have not been able to access before. Buy-side traders looking to execute large orders in excess of 5 days ADV, including in highly illiquid, small and mid-cap stocks, have access to real-time visibility, full transparency and maximum control over the bookbuilding and deal distribution process. They can proactively source liquidity and efficiently drive the bookbuilding process in real-time, on one automated platform, with the ability to make distribution adjustments throughout. What’s more, Appital users will be able to execute all deals through the Turquoise MTF, via a single point of access and with seamless straight-through-processing (STP) to over 20 settlement venues.

About Appital

Appital, the Equity Capital Marketplace, brings technological innovation and automation to equity capital markets, unlocking and uncovering liquidity for investors. The Appital platform allows the buy-side community to gain greater exposure to deal flow and execution opportunities in highly illiquid small and mid-cap stocks, often in excess of 5 days of ADV, with minimal market impact or risk of price erosion.

Appital’s distribution methodology is highly efficient, unbiased and unconflicted, delivering a fair outcome for all market participants. Appital’s buy-side community has access to real-time visibility, full transparency and maximum control over the bookbuilding and deal distribution process.

The Appital platform can be integrated into existing OMS and EMS systems and workflows, and the desktop application is also available on OpenFin. For more information please visit our website and follow us on Twitter @AppitalHQ and LinkedIn .

About FlexTrade :

FlexTrade Systems is a global leader in high performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world’s first broker-neutral, execution management trading system, which allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye